{"entity":{"id":"nct05060016","kind":"trial","name":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)","aka":[],"tldr":"A phase 2 trial of Tarlatamab in small-cell lung cancer, run by Amgen, active and no longer recruiting.","summary":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) is a phase 2 interventional study registered as NCT05060016 by Amgen, with 222 participants enrolled, started 2021-12-01 and due to reach its primary completion in 2027-12-30. Interventions recorded: Tarlatamab. Conditions listed: Relapsed/Refractory Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05060016","url":"https://clinicaltrials.gov/study/NCT05060016"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["tarlatamab"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05060016","phase":"2","setting":"A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301).","sponsor":"Amgen","enrolled":222,"outcomes":[]},"route":"/trials/nct05060016/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}]}}